ALLO (STOCKS)
Allogene Therapeutics, Inc. Common Stock
$2.890100
+0.170100 (+6.25%)
Prev close: $2.720000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- David D. Chang
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $745.96M
- Employees
- 361
- P/E (TTM)
- -3.13
- P/B (TTM)
- 2.13
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
11
Buy
2
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.17 | $-0.22 | +0.0507 | +22.97% |
|
Sep 2025 (Q3)
|
$-0.19 | $-0.23 | +0.0377 | +16.56% |
|
Jun 2025 (Q2)
|
$-0.23 | $-0.28 | +0.0490 | +17.56% |
|
Mar 2025 (Q1)
|
$-0.28 | $-0.30 | +0.0155 | +5.25% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $18.43M |
| Operating Expenses | $209.32M |
| Research and Development | $150.15M |
| Other Operating Expenses | $59.16M |
| Operating Income/Loss | -$209.32M |
| Income/Loss From Continuing Operations After Tax | -$190.89M |
| Income/Loss From Continuing Operations Before Tax | -$190.89M |
| Income/Loss From Equity Method Investments | $0.00 |
| Income Tax Expense/Benefit | $0.00 |
| Income Tax Expense/Benefit, Current | $0.00 |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Net Income/Loss | -$190.89M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$190.89M |
| Net Income/Loss Available To Common Stockholders, Basic | -$190.89M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.87 |
| Diluted Earnings Per Share | -$0.87 |
| Basic Average Shares | 220,622,669 |
| Diluted Average Shares | 220,622,669 |
| Assets | $415.91M |
| Current Assets | $257.75M |
| Cash | $258.30M |
| Noncurrent Assets | $158.16M |
| Fixed Assets | $72.84M |
| Other Non-current Assets | $85.32M |
| Liabilities | $123.36M |
| Current Liabilities | $32.51M |
| Accounts Payable | $4.27M |
| Wages | $10.24M |
| Other Current Liabilities | $18.00M |
| Noncurrent Liabilities | $90.85M |
| Equity | $292.54M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $292.54M |
| Liabilities And Equity | $415.91M |
| Net Cash Flow From Operating Activities | -$149.25M |
| Net Cash Flow From Operating Activities, Continuing | -$149.25M |
| Net Cash Flow From Investing Activities | $95.56M |
| Net Cash Flow From Investing Activities, Continuing | $95.56M |
| Net Cash Flow From Financing Activities | $30.16M |
| Net Cash Flow From Financing Activities, Continuing | $30.16M |
| Net Cash Flow | -$23.53M |
| Net Cash Flow, Continuing | -$23.53M |
| Comprehensive Income/Loss | -$190.53M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$190.53M |
| Other Comprehensive Income/Loss | $358.00K |